{
    "nct_id": "NCT03863080",
    "official_title": "A Phase 2a, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label Extension of RVT-1401 in Myasthenia Gravis Patients",
    "inclusion_criteria": "1. Male or female ≥ 18 years of age.\n2. Myasthenia Gravis Foundation of America (MGFA) Class II-IVa and likely not in need of a respirator for the duration of the study as judged by the Investigator.\n3. QMG score ≥12 at Screening and Baseline.\n\nOther, more specific inclusion criteria are defined in the protocol.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "1. Use of rituximab, belimumab, eculizumab or any monoclonal antibody for immunomodulation within 6 months prior to first dosing.\n2. Immunoglobulins given by SC, IV (IVIG), or intramuscular route, or plasmapheresis/plasma exchange (PE) within 4 weeks before Screening.\n3. Thymectomy performed < 12 months prior to screening.\n4. Total IgG level <6 g/L (at screening).\n5. Absolute neutrophil count <1500 cells/mm3(at screening).\n\nOther, more specific exclusion criteria are defined in the protocol",
    "miscellaneous_criteria": ""
}